ALPMF.US Astellas Pharma Inc

Healthcare Pharmaceuticals USA Stocks
16.55 USD
Close of Nov 13, 2026
10.88 18.03
Market cap
USD 29.7B
P/E
12.2x
P/B
2.38x
ROE
24.3%
Dividend yield
3.03%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.

Is ALPMF.US undervalued?

Graham number
Price16.55
Graham value14.60
Premium13.4%

ALPMF.US trades 13.4% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Astellas Pharma Inc fundamental analysis

No fundamental analysis for Astellas Pharma Inc yet.

Astellas Pharma Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Astellas Pharma Inc

Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associ…

Full company profile